The Priority Review

The stream · Daily digest

The stream: Sunday, October 25, 2026

4 briefs, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 4

  1. PRABITAS trial shows 14-day trifluridine-tipiracil plus bevacizumab non-inferior to 28-day schedule

    The authors reported that the 14-day schedule achieved a median overall survival of 11·3 months versus 10·3 months for the 28-day schedule, with a stratified hazard ratio of 0·93 (95% CI 0·80-1·08). Neutropenia grade 3 or worse was reduced by 25 percentage points (13% vs 39%) and anorexia grade 2 or worse by 11 percentage points (15% vs 26%).

    Source: PubMed record of a Phase III journal article, October 25, 2026

  2. Nivolumab plus ipilimumab shows significant OS benefit versus NIVO and chemotherapy

    The authors reported a hazard ratio of 0.61 versus NIVO across all lines and 0.37 versus chemotherapy in first-line therapy, with 95% confidence intervals of 0.46-0.82 and 0.24-0.57 respectively. Grade 3/4 treatment-related adverse events occurred in 22% of NIVO+IPI patients versus 14% of NIVO patients, with no new safety concerns.

    Source: PubMed record of a Phase III journal article, October 25, 2026

  3. Lilly presents durable first-line activity of olomorasib in KRAS G12C-mutant NSCLC at ESMO 2026

    Lilly reported that olomorasib plus pembrolizumab without chemotherapy achieved durable efficacy, with median progression-free survival not yet reached after a median follow-up of 20.7 months. In a separate rapid oral presentation, the combination with chemoimmunotherapy yielded a 62% investigator-assessed overall response rate and a median duration of response of 14.5 months.

    Source: Company press release (PR Newswire), October 25, 2026

  4. Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143

    Johnson & Johnson said that in a Phase 1 study of JNJ-6143, 75 percent (12 of 16) of patients with measurable disease achieved a confirmed complete or partial response. The company also noted that 77 percent of patients at the 50-mg dose had a confirmed PSA reduction of at least 50 percent, with 48 percent achieving reductions of at least 90 percent.

    Source: Company press release (PR Newswire), October 25, 2026